Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
714 (USA) · Dr. Clarke
consented 2013-08-15
AEs
1
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate ATRIOVENTRICULAR BLOCK SECOND DEGREE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-08-13 (study day -2.0); relationship: NONE
Data queries
No data queries.